Swipe Left For English News
1
坚定践行气候变化应对承诺，深度响应联合国可持续发展目标
2
积极响应“世界地球日”年度倡议——行动有你、地球有力，共塑可持续发展范式
上海,
2025年4月22日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布，公司凭借在应对气候变化领域的杰出表现和透明披露，得到全球环境非营利组织CDP的高度认可，连续两年获A-领导力级别评分。
CDP作为全球企业环境信息披露的“黄金标准”，其年度评级被视为衡量企业可持续发展能力的权威标尺。该评分体系通过“披露、认知、管理、领导力”四大层级，系统性评估企业对环境议题的理解深度与管理效能。2024年，全球逾25000家企业参与CDP评级，参评企业市值占比全球总市值三分之二。药明生物以亮眼表现再次获得气候变化领域领导力认可。
作为科学碳目标倡议（SBTi）的积极践行者，药明生物制定了应对气候变化的综合战略、科学目标矩阵及清晰路线图，承诺于2050年前实现运营净零排放。2024年，公司温室气体（范围一和范围二）排放密度较2020年基准年下降30%。此外，公司积极探索能耗降低举措，通过工艺优化、设备升级及基础设施改造、布局屋顶光伏发电项目等措施优化能源使用效率。目前，爱尔兰基地已实现100%可再生电力供应。
陈智胜
博士
药明生物首席执行官
ESG委员会主席
连续两年获CDP气候变化领导力评级，是对药明生物可持续发展战略的认可，更坚定了我们在可持续发展道路上继续前行的信心。值此世界地球日之际，全球共议永续发展，我们作为绿色生物药解决方案领域的全球领导者，期待与全球伙伴深化合作，凭借卓越的ESG理念立己达人，助力其迈向ESG发展新高度，共同推动整个价值链的可持续发展。
作为联合国全球契约组织（UNGC）和制药供应链倡议组织（PSCI）成员，药明生物积极倡导可持续发展的战略举措并赢得业界广泛认可。公司连续两年获得明晟（MSCI）最高AAA ESG评级、EcoVadis“铂金”评级、入选道琼斯可持续发展指数（DJSI）；凭借领先的绿色生物药解决方案（Green CRDMO），公司成功入选UNGC“‘二十年二十佳’企业可持续发展案例”报告；连续五年获评晨星Sustainalytics ESG“行业最高评级”及“区域最高评级”；连续两年荣登CDP水安全管理A级榜单；入选富时社会责任指数系列；入选恒生ESG 50指数；ISS ESG评级“最佳”奖章认可，充分彰显了公司在可持续发展领域的卓越表现。
关于CDP
CDP是一家全球性非营利组织，负责管理全球唯一的独立环境信息披露系统。作为环境报告领域的开创者，该组织始终秉持透明原则，致力于通过数据的力量推动变革。CDP与企业、资本、政策和科学领域的领导者紧密合作，提供支持地球可持续发展决策的关键信息。2024年，CDP帮助超过24800家企业和1100个城市、州及地区披露了其环境影响。目前，全球超过四分之一的机构资产所属的金融机构使用CDP数据指导投资和贷款决策。CDP以国际可持续发展准则理事会（ISSB）的气候标准IFRS S2为基准，整合了全球最佳实践报告标准和框架。其团队遍布全球，致力于实现“构建一个人、地球与经济效益和谐共生的世界”的美好愿景。
关于药明生物
药明生物（代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2024年12月底，药明生物帮助客户研发和生产的综合项目高达817个，其中包括21个商业化生产项目（不包括新冠项目）。
药明生物以可持续发展为长期业务增长的基石。公司持续推动绿色创新技术，为全球合作伙伴提供先进的端到端绿色CRDMO解决方案，同时在ESG方面不断取得卓越成就。秉承创造共享价值的理念，公司携手利益相关方构建可持续发展生态，通过负责任运营模式推动社会价值与生态效益双提升，实现全价值链的协同赋能。更多信息，请访问：www.wuxibiologics.com
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
1
Firm commitment to tackling climate change in support of United Nations Sustainable Development Goals
2
Earth Day 2025 - Our Power, Our Planet, Contribute to a sustainable future
Shanghai,
April 22, 2025
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized by CDP, the world's foremost environmental non-profit reporting organization, for its leadership in disclosure transparency and performance excellence in the area of climate change. This marks the second consecutive year the company has achieved this honor.
CDP is recognized as the global standard for corporate environmental reporting, and its annually published ratings are widely used to drive investment and procurement decisions toward a net-zero, sustainable and resilient economy. Companies are evaluated on their awareness of environmental issues, management methods and advancements in environmental stewardship. In 2024, nearly 25,000 companies — representing two-thirds of the global market value — reported their environmental data through CDP. WuXi Biologics stood out among these companies with an "A-" score for leadership on climate change.
Committed to the Science Based Target initiative (SBTi), WuXi Biologics has adopted an integrated strategy to tackle climate change issues, with measurable targets and a refined roadmap. The Company aims to achieve net-zero emissions from overall operations by 2050, and in 2024, it realized a 30% GHG (Scope 1 and Scope 2) emission intensity reduction from the base year 2020. The company also actively pursues opportunities to decrease energy consumption, advocating energy-saving initiatives from process optimization, equipment upgrade, and infrastructure replacement and renovation. The company actively deploys rooftop photovoltaic power projects, and has achieved a 100% renewable electricity supply at its Ireland site.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
We are very pleased to be recognized once again by CDP for climate change leadership, an acknowledgement that further inspires our steadfast dedication to enhancing our sustainability performance. It is fitting that we are making this announcement on Earth Day as we, along with organizations and communities around the world, put special focus on the importance of long-term ecological sustainability. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide with end-to-end solutions to fulfil their ESG commitments, and work together with all of our stakeholders to promote responsible practices throughout the entire value chain.
As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability, and has earned widespread recognition for its efforts. It was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI) for two consecutive years; included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; merited an "A" CDP Water Security score; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.
About CDP
CDP is a global non-profit that runs the world’s only independent environmental disclosure system. As the founder of environmental reporting, the organization believes in transparency and the power of data to drive change. Partnering with leaders in enterprise, capital, policy and science, CDP surfaces the information needed to enable Earth-positive decisions. It helped more than 24,800 companies and 1,100 cities, states and regions disclose their environmental impacts in 2024. Financial institutions with more than a quarter of the world’s institutional assets use CDP data to help inform investment and lending decisions. Aligned with the ISSB’s climate standard, IFRS S2, as its foundational baseline, CDP integrates best-practice reporting standards and frameworks in one place. The team is truly global, united by a shared desire to build a world where people, planet and profit are truly balanced.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
请点击右下角【爱心】，
并将公众号设为【星标】，
第一时间收到药明生物最新消息
2025-06-15
26页
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
收藏
登录后参与评论